154 related articles for article (PubMed ID: 33852630)
1. Evaluation of the antiproliferative effects of the HASPIN inhibitor CHR-6494 in breast cancer cell lines.
Nishida-Fukuda H; Tokuhiro K; Ando Y; Matsushita H; Wada M; Tanaka H
PLoS One; 2021; 16(4):e0249912. PubMed ID: 33852630
[TBL] [Abstract][Full Text] [Related]
2. Antitumor activity of a small-molecule inhibitor of the histone kinase Haspin.
Huertas D; Soler M; Moreto J; Villanueva A; Martinez A; Vidal A; Charlton M; Moffat D; Patel S; McDermott J; Owen J; Brotherton D; Krige D; Cuthill S; Esteller M
Oncogene; 2012 Mar; 31(11):1408-18. PubMed ID: 21804608
[TBL] [Abstract][Full Text] [Related]
3. Haspin inhibition delays cell cycle progression through interphase in cancer cells.
Wang P; Hua X; Bryner YH; Liu S; Gitter CB; Dai J
J Cell Physiol; 2020 May; 235(5):4508-4519. PubMed ID: 31625162
[TBL] [Abstract][Full Text] [Related]
4. Design of new disubstituted imidazo[1,2-
Elie J; Feizbakhsh O; Desban N; Josselin B; Baratte B; Bescond A; Duez J; Fant X; Bach S; Marie D; Place M; Ben Salah S; Chartier A; Berteina-Raboin S; Chaikuad A; Knapp S; Carles F; Bonnet P; Buron F; Routier S; Ruchaud S
J Enzyme Inhib Med Chem; 2020 Dec; 35(1):1840-1853. PubMed ID: 33040634
[TBL] [Abstract][Full Text] [Related]
5. HASPIN kinase inhibitor CHR-6494 suppresses intestinal polyp development, cachexia, and hypogonadism in Apcmin/+ mice.
Tanaka H; Wada M; Park J
Eur J Cancer Prev; 2020 Nov; 29(6):481-485. PubMed ID: 31833958
[TBL] [Abstract][Full Text] [Related]
6. HASPIN is involved in the progression of gallbladder carcinoma.
Zhu D; Gu X; Lin Z; Yu D; Wang J; Li L
Exp Cell Res; 2020 May; 390(2):111863. PubMed ID: 31987787
[TBL] [Abstract][Full Text] [Related]
7. Inhibition of Haspin Kinase Promotes Cell-Intrinsic and Extrinsic Antitumor Activity.
Melms JC; Vallabhaneni S; Mills CE; Yapp C; Chen JY; Morelli E; Waszyk P; Kumar S; Deming D; Moret N; Rodriguez S; Subramanian K; Rogava M; Cartwright ANR; Luoma A; Mei S; Brinker TJ; Miller DM; Spektor A; Schadendorf D; Riggi N; Wucherpfennig KW; Sorger PK; Izar B
Cancer Res; 2020 Feb; 80(4):798-810. PubMed ID: 31882401
[TBL] [Abstract][Full Text] [Related]
8. Coumestrol Epigenetically Suppresses Cancer Cell Proliferation: Coumestrol Is a Natural Haspin Kinase Inhibitor.
Kim JE; Lee SY; Jang M; Choi HK; Kim JH; Chen H; Lim TG; Dong Z; Lee KW
Int J Mol Sci; 2017 Oct; 18(10):. PubMed ID: 29064398
[TBL] [Abstract][Full Text] [Related]
9. 3H-pyrazolo[4,3-f]quinoline haspin kinase inhibitors and anticancer properties.
Opoku-Temeng C; Dayal N; Aflaki Sooreshjani M; Sintim HO
Bioorg Chem; 2018 Aug; 78():418-426. PubMed ID: 29698892
[TBL] [Abstract][Full Text] [Related]
10. Loss of haspin suppresses cancer cell proliferation by interfering with cell cycle progression at multiple stages.
Wang P; Hua X; Sun Y; Li H; Bryner YH; Hsung RP; Dai J
FASEB J; 2021 Oct; 35(10):e21923. PubMed ID: 34551143
[TBL] [Abstract][Full Text] [Related]
11. Sangivamycin and its derivatives inhibit Haspin-Histone H3-survivin signaling and induce pancreatic cancer cell death.
Bastea LI; Hollant LMA; Döppler HR; Reid EM; Storz P
Sci Rep; 2019 Nov; 9(1):16588. PubMed ID: 31719634
[TBL] [Abstract][Full Text] [Related]
12. Genome-wide CRISPR screen uncovers a synergistic effect of combining Haspin and Aurora kinase B inhibition.
Huang M; Feng X; Su D; Wang G; Wang C; Tang M; Paulucci-Holthauzen A; Hart T; Chen J
Oncogene; 2020 May; 39(21):4312-4322. PubMed ID: 32300176
[TBL] [Abstract][Full Text] [Related]
13. Modulation of the chromatin phosphoproteome by the Haspin protein kinase.
Maiolica A; de Medina-Redondo M; Schoof EM; Chaikuad A; Villa F; Gatti M; Jeganathan S; Lou HJ; Novy K; Hauri S; Toprak UH; Herzog F; Meraldi P; Penengo L; Turk BE; Knapp S; Linding R; Aebersold R
Mol Cell Proteomics; 2014 Jul; 13(7):1724-40. PubMed ID: 24732914
[TBL] [Abstract][Full Text] [Related]
14. Synthesis and evaluation of novel N1-acylated 5-(4-pyridinyl)indazole derivatives as potent and selective haspin inhibitors.
Shawky MM; Abdallah M; Khalifa H; Aboushady Y; Abadi AH; Engel M; Abdel-Halim M
Bioorg Chem; 2024 Apr; 145():107235. PubMed ID: 38447464
[TBL] [Abstract][Full Text] [Related]
15. Structure, Roles and Inhibitors of a Mitotic Protein Kinase Haspin.
Kestav K; Uri A; Lavogina D
Curr Med Chem; 2017; 24(21):2276-2293. PubMed ID: 28413956
[TBL] [Abstract][Full Text] [Related]
16. Function and inhibition of Haspin kinase: targeting multiple cancer therapies by antimitosis.
Liu Y; Yang H; Fang Y; Xing Y; Pang X; Li Y; Zhang Y; Liu Y
J Pharm Pharmacol; 2023 Apr; 75(4):445-465. PubMed ID: 36334086
[TBL] [Abstract][Full Text] [Related]
17. Structure-activity relationship study of acridine analogs as haspin and DYRK2 kinase inhibitors.
Cuny GD; Robin M; Ulyanova NP; Patnaik D; Pique V; Casano G; Liu JF; Lin X; Xian J; Glicksman MA; Stein RL; Higgins JM
Bioorg Med Chem Lett; 2010 Jun; 20(12):3491-4. PubMed ID: 20836251
[TBL] [Abstract][Full Text] [Related]
18. Structure-activity relationship study of beta-carboline derivatives as haspin kinase inhibitors.
Cuny GD; Ulyanova NP; Patnaik D; Liu JF; Lin X; Auerbach K; Ray SS; Xian J; Glicksman MA; Stein RL; Higgins JM
Bioorg Med Chem Lett; 2012 Mar; 22(5):2015-9. PubMed ID: 22335895
[TBL] [Abstract][Full Text] [Related]
19. Co-inhibition of Aurora A and Haspin kinases enhances survivin blockage and p53 induction for mitotic catastrophe and apoptosis in human colorectal cancer.
Lin CI; Chen ZC; Chen CH; Chang YH; Lee TC; Tang TT; Yu TW; Yang CM; Tsai MC; Huang CC; Yang TW; Lin CC; Wang RH; Chiou GY; Jong YJ; Chao JI
Biochem Pharmacol; 2022 Dec; 206():115289. PubMed ID: 36241092
[TBL] [Abstract][Full Text] [Related]
20. CRISPR/Cas9 screening identifies a kinetochore-microtubule dependent mechanism for Aurora-A inhibitor resistance in breast cancer.
Chen A; Wen S; Liu F; Zhang Z; Liu M; Wu Y; He B; Yan M; Kang T; Lam EW; Wang Z; Liu Q
Cancer Commun (Lond); 2021 Feb; 41(2):121-139. PubMed ID: 33471959
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
